New generation immunotherapy treatments for cancer are very effective. They target immune system control points and show impressive results in clinical trials. Unfortunately, they only work on a still limited population of patients. 

Indeed, the tumor microenvironment plays a crucial role in the effectiveness of these therapies and can, according to people, prevent therapeutic antibodies from penetrating well into the heart of the tumor. 

It is in this context that the team of Prof. Jean-Luc GALZI (Laboratory of Biotechnology and Cell Signaling - UMR 7242), in partnership with the Laboratory of Prof. Marcel HIBERT (Laboratory of Therapeutic Innovation - UMR 7200) is developing a research project to better target the tumor microenvironment, particularly by neutralizing the chemokines present.

The laboratory has thus developed a family of neutralizing molecules of CXCL12. Initial in vivo results have been obtained in inflammatory models of asthma and atopic dermatitis. The current project aims to demonstrate the efficacy of CXCL12 neutraligand in combination with immunotherapy treatment.